Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07400965 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
A Phase 2 study of Demodex Blepharitis, sponsored by Glaukos Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 1
- Study location
NCT07400965: Recruiting Phase 2 study of Demodex Blepharitis, sponsored by Glaukos Corporation.
NCT07400965 is a Phase 2 study of Demodex Blepharitis that is actively recruiting participants, run by Glaukos Corporation. The registered enrollment target is 250 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07400965, a Phase 2 study of Demodex Blepharitis, is actively recruiting participants, sponsored by Glaukos Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.
Primary Outcome
Percentage of study eyes that had eyelash collarettes due to Demodex blepharitis at the onset of treatment who demonstrate absence of collarettes after 6 weeks of treatment
Conditions Studied
Interventions
- DRUG GLK-321 low dose BID
- DRUG GLK-321 mid dose BID
- DRUG GLK-321 high dose BID
- DRUG GLK-321 high dose QD
- DRUG Placebo BID
Study Locations (1)
California
- Glaukos Clinical Study Site - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-12-05 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
What NCT07400965 shows while recruiting
NCT07400965 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% higher).
The record links to 1 condition, with Demodex Blepharitis appearing as the primary indexed condition, and to 5 interventions - of which GLK-321 low dose BID is the first listed.
NCT07400965 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07400965 about?
NCT07400965 is a clinical study titled "Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis". This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.
What is the current status of trial NCT07400965?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2025-12-05. Estimated completion is 2026-11.
What conditions does trial NCT07400965 study?
This clinical trial studies the following conditions: Demodex Blepharitis.
What interventions are being tested in trial NCT07400965?
The interventions under investigation include: GLK-321 low dose BID (DRUG), GLK-321 mid dose BID (DRUG), GLK-321 high dose BID (DRUG), GLK-321 high dose QD (DRUG), Placebo BID (DRUG).
Who is sponsoring clinical trial NCT07400965?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07400965 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Demodex Blepharitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07400965's enrollment target sits among peer trials
250 222nd of 2000 higher than 1,769 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI